Researcher
Els Van Nieuwenhuysen
- Disciplines:Gynaecology and obstetrics, Nursing, Endocrinology and metabolic diseases
Affiliations
- Department of Oncology (Department)
Member
From1 Sep 2015 → 31 Oct 2017 - Gynaecological Oncology (Division)
Member
From1 Aug 2012 → Today
Projects
1 - 4 of 4
- ORDECA – ORganoid Drug screening for Endometrial CAncerIdentifying novel drugs and biomarkers for treating endometrial cancer using a high-throughput patient-derived organoid drug discovery and screening platformFrom1 Oct 2023 → TodayFunding: IOF - technology validation in lab
- Abemaciclib and letrozole in ER positive rare ovarian cancerFrom1 Mar 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Efficacy of abemaciclib and letrozole in estrogen receptor-positive rare ovarian cancer and unravelling mechanisms of response and resistanceFrom1 Jan 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Exploring the heterogeneity of rare ovarian cancerDefining (epi)genomic transition from precursor lesion to invasive rare ovarian cancerFrom1 Apr 2020 → 1 Apr 2024Funding: Own budget, for example: patrimony, inscription fees, gifts
Publications
21 - 30 of 101
- Radical hysterectomy without adjuvant radiotherapy in patients with cervix carcinoma FIGO 2009 IB1, with or without positive Sedlis criteria(2021)
Authors: Toon Van Gorp, Els Van Nieuwenhuysen, Sileny Han, Anne-Sophie Van Rompuy, Patrick Neven, Ignace Vergote
Pages: 539 - 545 - Immunotherapy in rare ovarian cancer(2021)
Authors: Tina Laga, Ignace Vergote, Els Van Nieuwenhuysen
Pages: 447 - 456 - Comprehensive immunomolecular profiling of endometrial carcinoma: A tertiary retrospective study(2021)
Authors: Sara Vander Borght, Lien Spans, Hilde Brems, Annouschka Laenen, Ignace Vergote, Toon Van Gorp, Els Van Nieuwenhuysen, Sileny Han, Stefan Timmerman, Anne-Sophie Van Rompuy, et al.
Pages: 694 - 701 - High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification(2021)
Authors: Siel Olbrecht, Pieter Busschaert, Jun Qian, Liselore Loverix, Toon Van Gorp, Els Van Nieuwenhuysen, Sileny Han, An Coosemans, Anne-Sophie Van Rompuy, Diether Lambrechts, et al.
- Concordance between results of inexpensive statistical models and multigene signatures in patients with ER+/HER2-early breast cancer(2021)
Authors: Laurence Slembrouck, Isabelle Vanden Bempt, Hans Wildiers, Ann Smeets, Anne-Sophie Van Rompuy, Chantal Van Ongeval, Caroline Weltens, Kevin Punie, Els Van Nieuwenhuysen, Sileny Han, et al.
Pages: 1297 - 1309 - Cause of death for patients with breast cancer: discordance between death certificates and medical files, and impact on survival estimates(2021)
Authors: Hava Izci, Hans Wildiers, Kevin Punie, Eva Oldenburger, Els Van Nieuwenhuysen, Ann Smeets, Ines Nevelsteen, Patrick Neven
- Combination of weekly paclitaxel-carboplatin plus standard bevacizumab as neoadjuvant treatment in stage IB-IIB cervical cancer(2021)
Authors: Els Van Nieuwenhuysen, Sileny Han, Ignace Vergote
Pages: 824 - 828 - Robot-assisted surgery for women with endometrial cancer: Surgical and oncologic outcomes within a Belgium gynaecological oncology group cohort(2021)
Authors: Annouschka Laenen, Els Van Nieuwenhuysen, Ignace Vergote
Pages: 1117 - 1123 - Impact of clinical factors and surgical outcome on long-term survival in high-grade serous ovarian cancer: a multicenter analysis(2021)
Authors: Ignace Vergote, Els Van Nieuwenhuysen
Pages: 713 - 720 - Experience with PlasmaJet™ in debulking surgery in 87 patients with advanced-stage ovarian cancer(2021)
Authors: Els Van Nieuwenhuysen, Sileny Han, Toon Van Gorp, Ignace Vergote
Pages: 1109 - 1114